A review on integrating organ-on-chip microphysiological systems into early phase clinical trials for accelerated drug development
Keywords:
Organ-on-chip, microphysiological systems, drug development, Early phase clinical trials, in vitro modelsAbstract
Organ-on-chip (OOC) microphysiological systems have emerged as a promising alternative to traditional in vitro and animal models for drug development. These advanced platforms recreate the complex microenvironment and physiological functions of human organs, enabling more accurate predictions of drug efficacy and toxicity. The complex tissue-tissue interfaces, biochemical gradients, and mechanical cues found in vivo can be simulated effectively by OOC systems providing a powerful way for preclinical drug screening and testing. The integration of OOC systems into early phase clinical trials has the potential to revolutionize drug development by bridging the gap between preclinical studies and human clinical outcomes. This approach allows for the evaluation of drug candidates in a more physiologically relevant context, taking into account factors such as organ-specific responses, inter-individual variability, and disease-specific conditions. The incorporation of patient-derived cells and the development of multi-organ platforms further enhance the predictive power of OOC systems, enabling personalized medicine approaches and the assessment of systemic effects. However, challenges such as standardization, validation, scalability, and regulatory acceptance need to be addressed to fully realize the potential
of OOC systems in clinical settings. As the knowledge on OOC systems advances, their integration into early phase clinical trials is expected to streamline the drug development process, reduce the reliance on animal testing, and accelerate the translation of basic research into safe and effective therapies for patients.
Downloads
Metrics
References
DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20-33.
Bethi S, Wagh V, Bidkar S, Thorat M, Patil N. In-silico Drug Repurposing of Abiraterone-based Compounds as 17α-Hydroxylase Inhibitors for Breast Cancer Treatment Using Drug-Drug Transcriptomic Similarity Analysis and Molecular Docking. Int J Drug Deliv Technol. 2024;14(1):285-292.
Sams-Dodd F. Target-based drug discovery: is something wrong? Drug Discov Today. 2005;10(2):139-147.
Maschmeyer I, Lorenz AK, Schimek K. A four-organ-chip for interconnected long-term co-culture of human intestine, liver, skin and kidney equivalents. Lab Chip. 2015;15(12):2688-2699.
Ronaldson-Bouchard K, Vunjak-Novakovic G. Organs-on-a-chip: a fast track for engineered human tissues in drug development. Cell Stem Cell. 2018;22(3):310-324.
Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32(8):760-772.
Ronaldson-Bouchard K, Ma SP, Yeager K, Chen T, Song L, Upadhyaya S. Advanced maturation of human cardiac tissue grown from pluripotent stem cells. Nature. 2018;556:239-243.
Ahmed FE, Wunder SL, Goodsitt M, Khoo C, Pagliaro LC, Nada O. Preservation of micro-architecture and spatiotemporal cytokine secretion in a microfluidic model of human lung. Lab Chip. 2020;20(18):3298-3309.
Wikswo JP. The relevance and potential roles of microphysiological systems in biology and medicine. Exp Biol Med Maywood. 2014;239(9):1061-1072.
Hartung T, FitzGerald RE, Jennings P, Mirams GR, Peitsch MC, Rostami-Hodjegan A. Systems toxicology: real world applications and opportunities. Chem Res Toxicol. 2017;30(4):870-882.
Edmondson R, Broglie JJ, Adcock AF, Yang L. Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay Drug Dev Technol. 2014;12(4):207-218.
Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U A. 2013;110(9):3507-3512.
Mak IW, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res. 2014;6(2):114-118.
Hutchinson L, Kirk R. High drug attrition rates–where are we going wrong? Nat Rev Clin Oncol. 2011;8(4):189-190.
Krzyzanowska MK, Pintilie M, Tannock IF. Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA. 2003;290(4):495-501.
Zhang B, Radisic M. Organ-on-a-chip devices advance to market. Lab Chip. 2017;17(14):2395-2420.
Ahn J, Kim H, Lee SH. Organ-on-a-chip: technology convergence for future medicine. Chonnam Med J. 2020;56(1):1-5.
Gupta N, Liu P JR, B S, DE V, B G, V. Organ-on-chip models: implications in drug discovery and clinical applications. J Clin Pharmacol. 2019;59 Suppl 1:S103-S119.
Sung JH, Esch MB, Prot JM. Microfabricated mammalian organ systems and their integration into models of whole animals and humans. Lab Chip. 2013;13(7):1201-1212.
Ewart L, Dehne E, Fabre K, Gibbs J, Hickman D, Shuler M. Application of microphysiological systems to enhance safety assessment in drug discovery. Annu Rev Pharmacol Toxicol. 2017;57:65-82.
Vyas KB, Channawar MA, Dalal JS, Chandewar AV, Jumade PP, Vyas UB. Formulation Development and Evaluation of Microemulsion Loaded Hydrogel Systems with Plant Bioactives in Combination for Treatment of Psoriasis. Int J Drug Deliv Technol. 2024;14(1):405-411.
Vernetti L, Gough A, Baetz N, Blutt S, Broughman B JR, J.A. Functional coupling of human microphysiology systems: intestine, liver, kidney proximal tubule, blood-brain barrier and skeletal muscle. Sci Rep. 2017;7(1). doi:10.1038/srep42296
Vernetti LA, Vogt A, Gough A, Taylor DL. Evolution of experimental models of the liver to predict human drug hepatotoxicity and efficacy. Clin Liver Dis. 2017;21(1):197-214.
Stucki AO, Stucki JD, Hall F SR, M M, Y S, R.A. A lung-on-a-chip array with an integrated bio-inspired respiration mechanism. Lab Chip. 2018;18(6):882-894.
Workman MJ, Gleeson JP, Troisi EJ. Enhanced Utilization of Induced Pluripotent Stem Cell–Derived Human Intestinal Organoids Using Microengineered Chips. Cell Mol Gastroenterol Hepatol. 2018;5(4):669-677.
Velve-Casquillas G, Le Berre M, Piel M, Tran PT. Microfluidic tools for cell biological research. Nano Today. 2010;5(1):28-47.
Salih OS, Al-akkam EJ. Microneedles as A Magical Technology to facilitate Transdermal Drug Delivery: A Review Article. Int J Drug Deliv Technol. 2022;12(2):896-901.
Salaemae W, Azam AM, Booker-Milburn KI. A microfluidic in vitro model of the gastrointestinal human-microbe interface. Nat Commun. 2016;7(11135).
Salaemae W, Booker-Milburn KI, Azam ATM. Pharmacokinetic Modelling to Aid Drug Development: Which Models Can Be Trusted? Pharm Res. 2018;35(12).
Breckenridge A, Jacob R. Overcoming the legal and regulatory barriers to the in vitro testing of human drugs and chemicals by integrating microPhysiological systems (MPS) into early pharmaceutical development. Altern Lab Anim. 2019;47(1):14-27.
Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J. Organoid Modeling of the Tumor Immune Microenvironment. Cell. 2018;175(7):1972-1988.
Choudhury D, Toh YC, Yu H. Organoid technologies meet genome engineering for disease modeling. Hum Genet. 2020;139(1):137-159.
Lee SH, Sung JH. Organ-on-a-Chip Technology for Reproducing Multiorgan Physiology. Adv Heal Mater. 2018;7(4).
34. Ma C, Peng Y, Li H, Chen W. Organ-on-a-Chip: A New Paradigm for Drug Development. Trends Pharmacol Sci. 2021;42(2):119-133. doi: 10.1016/j.tips.2020.11.009.
Oleaga C, Bernabini C, Smith AS, Srinivasan B, Jackson M, McLamb W. Multi-Organ toxicity demonstration in a functional human in vitro system composed of four organs. Sci Rep. 2016;6(20030).
Matera C, Puccinelli E, Cazzaniga M, Parravicini C, Pisignano G, Raimondi V. Preclinical Assessment of a Reconstituted Human Vascularized Organotypic Lung Tumor Model (rHOTM) to Evaluate Immunotherapy Approaches. Adv Sci Weinh. 2019;6(23).
Gonzalez A, Park SJ, Lim JE, Lim K, Chung S, Chung C. Microscale electrofluidic chips for in vitro drug studies on immobilized zebrafish embryos: Applications for developmental toxicity testing. Lab Chip. 2018;11;18(2):234-243.
Kilinc D, Peyrin JM, Soubrier AS, Magniez A, Ramonda M, Marliere V. Banking human pluripotent stem cell lines from healthy donors: good manufacturing practice conditions for the human liver-on-chip. Stem Cell Res Ther. 2018;3;9(1):107.
Burgstaller G, Stettler T, Merz M, Schmid D, Waßer S, Stucki AO. Industry-Oriented Scenarios for Adoption of Human Organ-On-a-Chip Technology: A Special Interest Group Opinion. SLAS Technol. 2020;25(4):349-355.
Ajalik RE, Alenchery RG, Cognetti JS, Zhang VZ, McGrath JL, Miller BL, Awad HA. Human Organ-on-a-Chip Microphysiological Systems to Model Musculoskeletal Pathologies and Accelerate Therapeutic Discovery. Front Bioeng Biotechnol. 2022 Mar 14;10:846230. doi: 10.3389/fbioe.2022.846230.
Yuan S, Yuan H, Hay DC, Hu H, Wang C. Revolutionizing Drug Discovery: The Impact of Distinct Designs and Biosensor Integration in Microfluidics-Based Organ-on-a-Chip Technology. Biosensors (Basel). 2024 Sep 3;14(9):425. doi: 10.3390/bios14090425.
Celikkin N, Presutti D, Maiullari F, Fornetti E, Agarwal T, Paradiso A, Volpi M, Święszkowski W, Bearzi C, Barbetta A, Zhang YS, Gargioli C, Rizzi R, Costantini M. Tackling Current Biomedical Challenges With Frontier Biofabrication and Organ-On-A-Chip Technologies. Front Bioeng Biotechnol. 2021 Sep 16;9:732130. doi: 10.3389/fbioe.2021.732130.
Ko J, Park D, Lee S, Gumuscu B, Jeon NL. Engineering Organ-on-a-Chip to Accelerate Translational Research. Micromachines (Basel). 2022 Jul 28;13(8):1200. doi: 10.3390/mi13081200.
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.